To investigate changes in cfDNA ESR1 mutations following endocrine therapy or chemotherapy and adjuvant treatment for more than 5 years, we created subgroups of patients who treated by NET, NAC, and AT in the PBC group. Here, ESR1 is linked to primary biliary cholangitis.